Baird maintains Twist Bioscience at Outperform, lowers price target to $135 from $187
Baird retained its Outperform rating for Twist Bioscience but reduced its price target from $187 to $135, a 27.8% decrease. This implies an 18.2% upside from the Nov 12 close of $114.22, according to the firm.
How this was made

The 30-second read
Why it matters
The downgrade may trigger short-term price decline and influence peer sentiment.
Market read
Analyst target cut is a fresh piece of information that could affect trading decisions on TWST.
What to watch
Potential upcoming product launches or partnerships not reflected in the target revision.
Background
Baird Research provides equity research coverage for Twist Bioscience, a synthetic biology company.
Ticker impact
Baird lowered Twist Bioscience's price target to $135 from $187.
likely downward pressure as investors reassess valuation.
A 27.8% target reduction signals weaker growth outlook, prompting sell pressure.
Market effects
May affect other synthetic biology stocks as analysts reassess sector valuations.
Limited to US biotech market.
Low global impact.
Counterpoint
Some investors may view the target cut as an entry point if they believe the market overreacted.
Key entities
- companyTwist Bioscience
Synthetic biology firm providing DNA synthesis services.
- analystBaird
Equity research firm issuing the price target revision.


